Zulkarnain Pulungan leads the designs and executions of studies on health economics and outcomes research (HEOR), predictive analytics, risk modeling, performance measurement, epidemiology, disease management evaluation, health disparity and social determinants of health.
Zulkarnain has a strong quantitative background with more than 20 years of analytic experience in designing and executing various health care studies. He has been with Inovalon for more than 11 years in various roles. Prior to joining Inovalon’s life sciences team, he was Principal Research Scientist at Avalere Health, where he led a team of analysts in projects including, but not limited to, HEOR studies related to heart failure, cancer, agitation in Alzheimer dementia patients, rheumatoid arthritis and pneumonia; epidemiology studies on various diseases; developing disease progression measures; health plan performance measure improvements; predictive models related to post-acute care settings and identifying patients with agitation; and identifying social drivers of health associated with poor quality performance.
Prior to joining Avalere, he led a team of analysts at Inovalon in various projects, including studies on disparities in outcomes in dual eligible and disadvantaged Medicare beneficiaries, star rating regional variation in Medicare Advantage issuers, socioeconomic risk adjustment on medication adherence measures, and healthcare utilization in the ACA population.
Before this, he specialized in quality measurement and improvement research at Leading Age New York and the Foundation for Long Term Care, where he developed, validated, and implemented quality measures and predictive models as part of innovative technology solutions to advance the use of data-driven decision making.
Zulkarnain received his Ph.D. in economics from the State University of New York at Albany, where he currently teaches a graduate level course in econometrics analysis.
Flare Frequency, Organ Damage, and Economic Burden Among Individuals With Immunoglobulin G4-Related Disease (IgG4-RD) in the United States
Accepted for presentation at International Society for Pharmacoeconomics and Outcomes Research. Findings available upon request. Contact us for more information.
Medicare Advantage vs. Traditional Fee-for-Service Medicare: Different Populations, Different Outcomes
Accepted for presentation at Academy of Managed Care Pharmacy. Findings available upon request. Contact us for more information.
Predictors of Timely Hypertension Treatment Escalation in the United States: Results from the Real-World BREAKTHROUGH Patient Registry
Accepted for presentation at American College of Cardiology (ACC.26). Findings available upon request. Contact us for more information.
Trends in Opioid Use Disorder Diagnoses, Hospitalizations, and Receipt of Recommended Therapy (2021–2024)
This retrospective analysis used Inovalon’s MORE² Registry® — a nationally representative closed-claims database — to evaluate trends in opioid use disorder (OUD) from 2021–2024 across three insured populations: commercially insured, Managed Medicaid, and Medicare Advantage.

Breaking Barriers to Advanced Parkinson’s Disease Treatment
This white paper explores how social drivers of health affect treatment access for patients with advanced Parkinson’s disease.

Medicare Advantage vs. Traditional Fee-for-Service Medicare: Different Populations, Different Outcomes
This study explores important differences in MA vs FFS populations and outcomes, challenging previous research and sharing key insights.